Oncothyreon Launches Phase 3 Clinical Trial


Oncothyreon Inc. (Nasdaq: ONTY) launched a global Phase 3 clinical trial of the cancer vaccine Stimuvax sending the stock price soaring 75 cents to close at $3.03.

About this Entry

This page contains a single entry by published on June 22, 2009 2:46 PM.

Rex Sells 50% Of Stake In Marcellus Shale was the previous entry in this blog.

LabCorp To Acquire Monogram is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Powered by Movable Type 5.12